Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
Crossref DOI link:
Published Online: 2017-01-23
Published Print: 2017-12
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Glueck, Charles J.
Funding for this research was provided by:
Jewish Hospital Lipoprotein Research Fund